Lenalidomide hemihydrateCAS# 847871-99-2 |
- Lenalidomide hydrochloride
Catalog No.:BCC1697
CAS No.:1243329-97-6
- Necrostatin-1
Catalog No.:BCC2247
CAS No.:4311-88-0
- Roquinimex
Catalog No.:BCC5355
CAS No.:84088-42-6
- Lenalidomide hemihydrate
Catalog No.:BCC4198
CAS No.:847871-99-2
- Necrostatin 2 racemate
Catalog No.:BCC2077
CAS No.:852391-15-2
- Necrostatin 2 S enantiomer
Catalog No.:BCC2078
CAS No.:852391-20-9
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 847871-99-2 | SDF | Download SDF |
PubChem ID | 46220375 | Appearance | Powder |
Formula | C13H13N3O3 | M.Wt | 259.26 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Synonyms | CC-5013 hemihydrate | ||
Solubility | DMSO : 50 mg/mL (186.38 mM; Need ultrasonic) H2O : < 0.1 mg/mL (insoluble) | ||
Chemical Name | 3-(7-amino-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione;hydrate | ||
SMILES | C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3N.C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3N.O | ||
Standard InChIKey | OTJHSDXKMBRCMM-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/2C13H13N3O3.H2O/c2*14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18;/h2*1-3,10H,4-6,14H2,(H,15,17,18);1H2 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Lenalidomide hemihydrate is a potent inhibitor of TNF-α and has antiangiogenic effect. Lenalidomide functions as a protein homeostatic modulator (PHM) linking casein kinase 1A1 (CKIα) to the human E3 ligase cereblon.In Vitro:Lenalidomide is potent in stimulating T cell proliferation and IFN-γ and IL-2 production. Lenalidomide has been shown to inhibit production of pro inflammatory cytokines TNF-α, IL-1, IL-6, IL-12 and elevate the production of anti-inflammatory cytokine IL-10 from human PBMCs. Lenalidomide downregulates the production of IL-6 directly and also by inhibiting multiple myeloma (MM) cells and bone marrow stromal cells (BMSC) interaction, which augments the apoptosis of myeloma cells[2]. Dose-dependent interaction with the CRBN-DDB1 complex is observed with Thalidomide, Lenalidomide and Pomalidomide, with IC50 values of ~30 μM, ~3 μM and ~3 μM, respectively, These reduced CRBN expression cells (U266-CRBN60 and U266-CRBN75) are less responsive than the parental cells to antiproliferative effects Lenalidomide across a dose-response range of 0.01 to 10 μM[3]. Lenalidomide, a thalidomide analog, functions as a molecular glue between the human E3 ubiquitin ligase cereblon and CKIα is shown to induce the ubiquitination and degradation of this kinase, thus presumably killing leukemic cells by p53 activation[5].In Vivo:The toxicity of Lenalidomide doses up to 15, 22.5, and 45 mg/kg via IV, IP, and PO routes of administration. Limited by solubility in our PBS dosing vehicle, these maximum achievable Lenalidomide doses are well tolerated with the exception of one mouse death (of four total dosed) at the 15 mg/kg IV dose. Notably, no other toxicities are observed in the study at IV doses of 15 mg/kg (n=3) or 10 mg/kg (n=45) or at any other dose level through IV, IP, and PO routes[4]. References: |
Lenalidomide hemihydrate Dilution Calculator
Lenalidomide hemihydrate Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 3.8571 mL | 19.2857 mL | 38.5713 mL | 77.1426 mL | 96.4283 mL |
5 mM | 0.7714 mL | 3.8571 mL | 7.7143 mL | 15.4285 mL | 19.2857 mL |
10 mM | 0.3857 mL | 1.9286 mL | 3.8571 mL | 7.7143 mL | 9.6428 mL |
50 mM | 0.0771 mL | 0.3857 mL | 0.7714 mL | 1.5429 mL | 1.9286 mL |
100 mM | 0.0386 mL | 0.1929 mL | 0.3857 mL | 0.7714 mL | 0.9643 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Lenalidomide (Revlimid, CC-5013) is a TNF-α secretion inhibitor with IC50 of 13 nM.
- S 32212 hydrochloride
Catalog No.:BCC6208
CAS No.:847871-78-7
- Tasumatrol L
Catalog No.:BCN6955
CAS No.:847835-17-0
- ICG 001
Catalog No.:BCC3632
CAS No.:847591-62-2
- NVP-BEP800
Catalog No.:BCC2129
CAS No.:847559-80-2
- SHA 68
Catalog No.:BCC6210
CAS No.:847553-89-3
- CEP-18770
Catalog No.:BCC2093
CAS No.:847499-27-8
- Eriocalyxin B
Catalog No.:BCN4390
CAS No.:84745-95-9
- Qingyangshengenin
Catalog No.:BCN4389
CAS No.:84745-94-8
- Calceolarioside A
Catalog No.:BCN5347
CAS No.:84744-28-5
- UVI 3003
Catalog No.:BCC7638
CAS No.:847239-17-2
- Arglabin
Catalog No.:BCC5299
CAS No.:84692-91-1
- Astragaloside IV
Catalog No.:BCN5960
CAS No.:84687-43-4
- RO4929097
Catalog No.:BCC2089
CAS No.:847925-91-1
- Lck Inhibitor
Catalog No.:BCC1689
CAS No.:847950-09-8
- 5-Epilithospermoside
Catalog No.:BCN4392
CAS No.:84799-31-5
- threo-1-(4-Hydroxy-3-methoxyphenyl)propane-1,2-diol
Catalog No.:BCN1331
CAS No.:848031-94-7
- 3,4-Dimethoxyphenyl beta-D-glucoside
Catalog No.:BCN4393
CAS No.:84812-00-0
- HKI 357
Catalog No.:BCC6046
CAS No.:848133-17-5
- Alvelestat
Catalog No.:BCC4058
CAS No.:848141-11-7
- EX-527 S-enantiomer
Catalog No.:BCC5594
CAS No.:848193-68-0
- EX-527 R-enantiomer
Catalog No.:BCC5595
CAS No.:848193-69-1
- SSR128129E
Catalog No.:BCC4498
CAS No.:848318-25-2
- AS 602801
Catalog No.:BCC1369
CAS No.:848344-36-5
- NCH 51
Catalog No.:BCC2422
CAS No.:848354-66-5
Lenalidomide, an antineoplastic drug, and its hemihydrate.[Pubmed:19805881]
Acta Crystallogr C. 2009 Oct;65(Pt 10):o502-5.
The crystal structures of lenalidomide [systematic name: (RS)-3-(4-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione], C13H13N3O3, (I), an antineoplastic drug, and its hemihydrate, C13H13N3O3.0.5H2O, (II), have been determined by single-crystal X-ray diffraction analysis. The overall conformation of the molecule defined by the orientation of the two ring portions, viz. pyridinedione and isoindolinone, is twisted in both structures. The influence of the self-complementary pyridinedione ring is seen in the crystal packing of both structures through its involvement in forming hydrogen-bonded dimers, although alternate dione O atoms are utilized. An extensive series of N-H...O hydrogen bonds link the dimers into two-dimensional supramolecular arrays built up from infinite chains. The water molecule in (II) has a cohesive function, connecting three lenalidomide molecules by hydrogen bonds. The significance of this study lies in the analysis of the interactions in these structures and the aggregations occurring via hydrogen bonds in the hydrated and dehydrated crystalline forms of the title compound.